As per the agreement, Minophagen will have the exclusive rights to develop and commercialize the drug candidate.
Eisai holds the right of first negotiation for the commercialization of the agent in the licensed territories, if it is approved.
Eisai is eligible to receive a one-time payment upon conclusion of the agreement, milestone payments and royalties on future sales, from Minophagen.
FDA had granted orphan drug status to bexarotene in 1999, and is presently approved and marketed as a treatment for recurrent and refractory CTCL in over 20 countries.